(NASDAQ: FLGT) Fulgent Genetics's forecast annual revenue growth rate of 11.18% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.18%.
Fulgent Genetics's revenue in 2026 is $322,671,000.On average, 5 Wall Street analysts forecast FLGT's revenue for 2026 to be $11,094,369,712, with the lowest FLGT revenue forecast at $10,586,871,942, and the highest FLGT revenue forecast at $11,465,077,314. On average, 5 Wall Street analysts forecast FLGT's revenue for 2027 to be $12,445,719,158, with the lowest FLGT revenue forecast at $11,670,574,872, and the highest FLGT revenue forecast at $13,322,362,999.
In 2028, FLGT is forecast to generate $13,827,986,931 in revenue, with the lowest revenue forecast at $12,958,526,136 and the highest revenue forecast at $14,585,329,757.